Posted in Provenge, tagged advanced prostate cancer, catheter, Dendreon, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, Provenge, Provenge treatment, WALL ST JOURNAL on August 6, 2010| Leave a Comment »
WALL ST JOURNAL: New wonder drug for treating advanced prostate cancer, Provenge, is finally making money for its manufacturer, Dendreon Corp. READ MORE>
Since the $93,000 treatment was launched at the beginning of May, doctors have written 500 prescriptions for the treatment, the company disclosed.
Posted in Gleason grade, PROSTATE CANCER, PROSTATE RESEARCH, tagged cancer research, catheter, Gleason score, medical checkups, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer seriousness, prostate test, Screening debate, WALL ST JOURNAL on July 21, 2010| Leave a Comment »
WALL ST JOURNAL: Scientists may soon be able to answer the agonising question facing men with prostate cancer: Does their cancer need immediate treatment or can it be left alone? READ MORE>
AND: Some men with low Gleason scores have cancer that spreads quickly, while some with high scores don’t. READ MORE>
Posted in PROSTATE CANCER, Provenge, tagged advanced prostate cancer, catheter, Centers for Medicare and Medicaid Services, Dendreon company, expensive immunotherapy treatment for prostate cancer, private insurers, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment debate, Provenge treatment, WALL ST JOURNAL on July 4, 2010| Leave a Comment »
WALL ST JOURNAL: The US government says it will begin analysis on whether the Dendreon company’s expensive immunotherapy treatment for prostate cancer – Provenge – is “reasonable and necessary.” READ MORE> (you need to subscribe)
The answer to that debate – the latest hurdle in Dendreon’s push to get Provenge used – will affect sales of the costly treatment.
If the Centers for Medicare and Medicaid Services covers it, that would increase the number of patients eligible and likely prompt private insurers to do the same. A denial by CMS could severely stifle the product’s growth.
Posted in Diagnosis, PROSTATE CANCER, PROSTATE RESEARCH, SCREENING and DIAGNOSIS, tagged cancer research, catheter, medical checkups, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer diagnosis, prostate cancer screening, prostate risk, Screening debate, WALL ST JOURNAL on June 30, 2010| Leave a Comment »
WALL ST JOURNAL: Scientists may soon be able to answer the agonising question facing men with prostate cancer: does their cancer need immediate treatment or can it be left alone? READ MORE> and HERE> and HERE>
Posted in Chemotherapy, New prostate drugs, PROSTATE CANCER, tagged advanced prostate cancer, cancer research, catheter, chemotherapy drug, Jevtana, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, steroid prednisone, U.S. Food and Drug Administration, WALL ST JOURNAL on June 20, 2010| Leave a Comment »
WALL ST JOURNAL: The US Food and Drug Administration has approved Jevtana, a chemotherapy drug used in combination with the steroid prednisone to treat men with advanced prostate cancer. READ MORE> and HERE>
Posted in PROSTATE CANCER, Treatment news, tagged comparison of treatments, Dartmouth University, decision aids, Foundation for Informed Medical Decision Making, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, treatment decisions, WALL ST JOURNAL on August 5, 2009| Leave a Comment »
AUGUST 5: WALL ST JOURNAL: “Decison aids” to help people decide on the best treatment for diseases like prostate cancer have been developed by the Foundation for Informed Medical Decision Making, which grew out of research at Dartmouth University in New Hampshire, US. READ MORE>
Posted in New prostate drugs, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged biopharmaceutical, cancer free, cancer research, Mayo Clinic, Medarex Inc. (MEDX), prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, WALL ST JOURNAL on June 24, 2009| Leave a Comment »
JUNE 24: WALL ST JOURNAL: Shares of Medarex Inc. (MEDX) surged Monday on news that two patients taking the biopharmaceutical company’s prostate cancer treatment in a mid-stage trial are now cancer free. READ MORE>
